3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
24
Lung Neoplasms
10
Small Cell Lung Carcinoma
9
Mesothelioma, Malignant
5
Squamous Cell Carcinoma of Head and Neck
4
Melanoma
4
Mesothelioma
3
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Non-small Cell Lung Cancer
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Part A and B: Advanced Solid Malignancies
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non Small Cell Lung Cancer NSCLC
1
Non - Small Cell Lung Cancer NSCLC
1
Neoplasms
1
Lung Cancer Metastatic
1
Kidney Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
EGFR Mutant Advanced Non Small Cell Lung Cancer
1
Disease Progression
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Carcinoma, Renal Cell
1
Interventions
durvalumab
2
tremelimumab
1
ceralasertib
1
aflutinib
1
Radiotherapy
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non Small Cell Lung Cancer NSCLC
×
tremelimumab
×
Thoracic
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA